REGENERON PHARMACEUTICALS, INC. financial data

Symbol
REGN on Nasdaq
Location
Tarrytown, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 28 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 456% % -16%
Quick Ratio 82% % 3.4%
Debt-to-equity 28% % 3.2%
Return On Equity 15% % -9.1%
Return On Assets 12% % -9.8%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $113,800,000,000 USD 48%
Weighted Average Number of Shares Outstanding, Basic 103,600,000 shares -4.2%
Weighted Average Number of Shares Outstanding, Diluted 107,200,000 shares -7.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $14,247,800,000 USD 2.9%
Research and Development Expense $5,636,200,000 USD 15%
Costs and Expenses $10,559,600,000 USD 6.9%
Operating Income (Loss) $3,688,200,000 USD -7.2%
Nonoperating Income (Expense) $1,456,900,000 USD 46%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $5,145,100,000 USD 3.5%
Income Tax Expense (Benefit) $567,100,000 USD 80%
Net Income (Loss) Attributable to Parent $4,578,000,000 USD -1.6%
Earnings Per Share, Basic 43 USD/shares 0.53%
Earnings Per Share, Diluted 41 USD/shares 3.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,506,400,000 USD 25%
Marketable Securities, Current $5,937,200,000 USD -24%
Accounts Receivable, after Allowance for Credit Loss, Current $5,687,100,000 USD -6.9%
Inventory, Net $3,254,400,000 USD 7.8%
Assets, Current $17,980,700,000 USD -7%
Deferred Income Tax Assets, Net $3,846,700,000 USD 28%
Operating Lease, Right-of-Use Asset $217,400,000 USD 179%
Intangible Assets, Net (Excluding Goodwill) $1,380,900,000 USD 23%
Other Assets, Noncurrent $1,673,100,000 USD 60%
Assets $40,169,400,000 USD 7.3%
Accounts Payable, Current $903,800,000 USD 82%
Employee-related Liabilities, Current $640,900,000 USD 3.7%
Contract with Customer, Liability, Current $545,600,000 USD -13%
Liabilities, Current $4,425,100,000 USD 21%
Contract with Customer, Liability, Noncurrent $219,200,000 USD 5.7%
Operating Lease, Liability, Noncurrent $204,100,000 USD 197%
Other Liabilities, Noncurrent $1,861,800,000 USD 21%
Liabilities $9,211,600,000 USD 13%
Accumulated Other Comprehensive Income (Loss), Net of Tax $69,000,000 USD 15%
Retained Earnings (Accumulated Deficit) $35,045,800,000 USD 14%
Stockholders' Equity Attributable to Parent $30,957,800,000 USD 5.6%
Liabilities and Equity $40,169,400,000 USD 7.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,045,100,000 USD -31%
Net Cash Provided by (Used in) Financing Activities $1,089,200,000 USD -2413%
Net Cash Provided by (Used in) Investing Activities $647,500,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $604,000,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,513,100,000 USD 25%
Deferred Tax Assets, Gross $3,407,100,000 USD 30%
Operating Lease, Liability $234,400,000 USD 167%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $4,586,800,000 USD -6.2%
Lessee, Operating Lease, Liability, to be Paid $290,900,000 USD 182%
Operating Lease, Liability, Current $30,300,000 USD 59%
Lessee, Operating Lease, Liability, to be Paid, Year Two $44,800,000 USD 123%
Lessee, Operating Lease, Liability, to be Paid, Year One $43,100,000 USD 79%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $56,500,000 USD 262%
Lessee, Operating Lease, Liability, to be Paid, Year Three $42,600,000 USD 173%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares 0%
Unrecognized Tax Benefits $1,313,700,000 USD 89%
Lessee, Operating Lease, Liability, to be Paid, Year Four $33,200,000 USD 168%
Additional Paid in Capital $13,787,300,000 USD 8.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $126,900,000 USD 11%
Interest Expense $71,100,000 USD 11%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%